Last reviewed · How we verify
treatment Vincristin
Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, causing cell cycle arrest in metaphase and triggering apoptosis in cancer cells.
Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, causing cell cycle arrest in metaphase and triggering apoptosis in cancer cells. Used for Acute lymphoblastic leukemia (ALL), Hodgkin lymphoma, Non-Hodgkin lymphoma.
At a glance
| Generic name | treatment Vincristin |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Drug class | Vinca alkaloid |
| Target | Tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vincristine inhibits the polymerization of tubulin dimers into microtubules, which are essential for mitotic spindle formation during cell division. By preventing microtubule assembly, the drug traps cells in metaphase, leading to mitotic arrest and subsequent programmed cell death. This mechanism is particularly effective against rapidly dividing cancer cells.
Approved indications
- Acute lymphoblastic leukemia (ALL)
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Small cell lung cancer
- Breast cancer
- Testicular cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Constipation
- Alopecia
- Nausea/vomiting
- Fatigue
- Jaw pain
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- treatment Vincristin CI brief — competitive landscape report
- treatment Vincristin updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI